Biocon Project
Study of an Indian public-listed company
BIOCON
Final Project Report
Contents
Background 3
Subsidiary Companies 4
Products and Services 4
The Auditors report 5
The Director’s Report 6
Accounting Policies 7
Balance sheet 14
Cash flow analysis 18
ANNEXURES 21
Ratio Analysis 23
New Terminologies 29
References 30
Background
Established in 1978, Biocon is India 's premier biotechnology company. Headquartered in Bangalore Biocon has evolved from an enzyme company to a fully integrated biopharmaceutical enterprise, focused on healthcare. In 2007, Biocon made a strategic decision to divest its historic enzymes business to Novozymes A/S of Denmark. Biocon now strategically focuses its activities on its bio-pharma business verticals that include APIs, biologicals and proprietary molecules both commercialized and under development with this divestment, the company mission is to 'Develop novel & affordable Biotherapeutics for global markets '.
Biocon Limited and its two subsidiary companies, Syngene International Limited and Clinigene International Limited form a fully integrated biotechnology enterprise specializing in biopharmaceuticals, custom research and clinical research. Biocon 's integrated business approach has enabled the company to establish a significant presence in the global biopharmaceutical market via its product offerings and customised, high value solutions at any stage in the lifecycle of a drug-from discovery to market. Biocon’s vision is to be an integrated biopharmaceutical enterprise of global distinction.
The company applies its proprietary fermentation technologies to make effective and innovative biomolecules in diabetology, oncology, cardiology and other therapeutic segments. Biocon 's products in the biopharmaceutical category include: anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-oxidants, biologicals, cholesterol-lowering agents, haemostatic agents,
BIOCON
Final Project Report
Contents
Background 3
Subsidiary Companies 4
Products and Services 4
The Auditors report 5
The Director’s Report 6
Accounting Policies 7
Balance sheet 14
Cash flow analysis 18
ANNEXURES 21
Ratio Analysis 23
New Terminologies 29
References 30
Background
Established in 1978, Biocon is India 's premier biotechnology company. Headquartered in Bangalore Biocon has evolved from an enzyme company to a fully integrated biopharmaceutical enterprise, focused on healthcare. In 2007, Biocon made a strategic decision to divest its historic enzymes business to Novozymes A/S of Denmark. Biocon now strategically focuses its activities on its bio-pharma business verticals that include APIs, biologicals and proprietary molecules both commercialized and under development with this divestment, the company mission is to 'Develop novel & affordable Biotherapeutics for global markets '.
Biocon Limited and its two subsidiary companies, Syngene International Limited and Clinigene International Limited form a fully integrated biotechnology enterprise specializing in biopharmaceuticals, custom research and clinical research. Biocon 's integrated business approach has enabled the company to establish a significant presence in the global biopharmaceutical market via its product offerings and customised, high value solutions at any stage in the lifecycle of a drug-from discovery to market. Biocon’s vision is to be an integrated biopharmaceutical enterprise of global distinction.
The company applies its proprietary fermentation technologies to make effective and innovative biomolecules in diabetology, oncology, cardiology and other therapeutic segments. Biocon 's products in the biopharmaceutical category include: anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-oxidants, biologicals, cholesterol-lowering agents, haemostatic agents,
References: 1. INSIGHT - http://insight.religaretechnova.com/home.htm 2. BIOCON official site – http://www.biocon.com